SNSS : Summary for Sunesis Pharmaceuticals, Inc. - Yahoo Finance

U.S. Markets closed

Sunesis Pharmaceuticals, Inc. (SNSS)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.29+0.10 (+2.39%)
At close: 4:00PM EST
People also watch
CYCCTHLDRPRXAEZSSNTA
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close4.19
Open4.25
Bid2.14 x 100
Ask4.35 x 1600
Day's Range4.11 - 4.33
52 Week Range2.64 - 6.30
Volume62,503
Avg. Volume50,306
Market Cap89.57M
Beta1.14
PE Ratio (TTM)-1.47
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Emergent (EBS) Beats Earnings, Revenue Estimates in Q4
    Zacksyesterday

    Emergent (EBS) Beats Earnings, Revenue Estimates in Q4

    Emergent BioSolutions, Inc. (EBS) reported earnings of 74 cents per share in the fourth quarter of 2016, which surpassed the Zacks Consensus Estimate of 60 cents. However, the reported figure decreased from 77 cents earned in the year-ago period.

  • Bayer (BAYRY) Misses on Q4 Earnings; Revenues in Line
    Zacks3 days ago

    Bayer (BAYRY) Misses on Q4 Earnings; Revenues in Line

    Bayer AG's (BAYRY) fourth-quarter 2016 core earnings increased 10.2% year over year to ???1.19 per share (approximately $1.28). Reported earnings missed the Zacks Consensus Estimate of $1.37.

  • Pfizer's Leukemia Candidate Gets Priority Review in U.S.
    Zacks3 days ago

    Pfizer's Leukemia Candidate Gets Priority Review in U.S.

    Pfizer Inc. (PFE) announced that its Biologics License Application (BLA) for leukemia candidate inotuzumab ozogamicin has been accepted for priority review by the FDA.